Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France.
Clin Nucl Med. 2013 Aug;38(8):630-5. doi: 10.1097/RLU.0b013e31829af5bf.
Secondary hyperparathyroidism (sHPT) is a major complication for patients with end-stage renal disease on long-term hemodialysis or peritoneal dialysis. When the disease is resistant to medical treatment, patients with severe sHPT are typically referred for parathyroidectomy (PTx), which usually improves biological parameters as well as clinical signs and symptoms. Unfortunately, early surgical failure with persistent disease may occur in 5%-10% of patients and recurrence reaches 20%-30% at 5 years. Presently, the use of parathyroid scintigraphy in sHPT is usually limited to the management of surgical failures after initial PTx. This review describes the strengths and limitations of typical (99m)Tc-sestamibi imaging protocols, and highlights the potential benefits of using parathyroid scintigraphy in the initial workup of surgical patients.
继发性甲状旁腺功能亢进症(sHPT)是长期接受血液透析或腹膜透析的终末期肾病患者的主要并发症。当疾病对药物治疗有抗性时,通常会建议严重 sHPT 的患者进行甲状旁腺切除术(PTx),这通常可以改善生物学参数以及临床症状和体征。不幸的是,在 5%-10%的患者中可能会发生早期手术失败且疾病持续存在,并且在 5 年内复发率达到 20%-30%。目前,在 sHPT 中使用甲状旁腺闪烁显像术通常仅限于初始 PTx 后手术失败的管理。本综述描述了典型的 (99m)Tc- sestamibi 成像方案的优缺点,并强调了在手术患者的初始评估中使用甲状旁腺闪烁显像术的潜在益处。